The Russian Direct Investment Fund (RDIF) may begin testing a combination of Sputnik V and a Chinese vaccine in Arab countries, RDIF head Kirill Dmitriev told reporters on the sidelines of SPIEF.
"We have received many requests from other vaccines, including Chinese vaccines for joint trials of the shots. These are major manufacturers, and perhaps we will start the first trials specifically in the Arab countries of combining Sputnik with a number of Chinese vaccines," he said.
Dmitriev has no doubt that the Russian Sputnik V vaccine will soon be recognized for movement in most countries.
"We have absolutely no doubt that Sputnik will soon be accepted for movement in most countries. We cannot ignore the 3.2 billion people who live in countries that have registered our vaccine," he said.
Sputnik V is based on a platform of human adenovirus vectors, and the vaccine has a 97.6% efficacy based on an analysis of coronavirus incidence data among Russians vaccinated with both components of the drug between December 5, 2020, and March 31, 2021.
GSV "Russia - Islamic World"
Photo: Creative Commons
Based on materials from TASS